Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome

Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome (also known as Malouf syndrome) is an extremely rare genetic disorder characterized by the combination of dilated cardiomyopathy and hypergonadotropic hypogonadism. Dilated cardiomyopathy involves enlargement and weakening of the heart's left ventricle, impairing its ability to pump blood effectively, which can lead to heart failure, arrhythmias, and potentially sudden cardiac death. Hypergonadotropic hypogonadism refers to gonadal dysfunction (ovarian or testicular failure) in the presence of elevated pituitary gonadotropins (FSH and LH), resulting in delayed puberty, absent or incomplete sexual development, and infertility. In females, streak ovaries and primary amenorrhea are commonly observed, while males may present with small testes and impaired spermatogenesis. Additional features reported in some patients include mild intellectual disability, facial dysmorphism (such as blepharoptosis and a broad nasal bridge), short stature, and skeletal anomalies. The syndrome has been linked to mutations in the LMNA gene, which encodes lamin A/C, a nuclear envelope protein involved in maintaining nuclear structure and function. Mutations in LMNA are known to cause a broad spectrum of diseases collectively termed laminopathies. Treatment is primarily supportive and symptom-based. Cardiac management may include standard heart failure therapies such as ACE inhibitors, beta-blockers, diuretics, and in severe cases, cardiac transplantation. Hormonal replacement therapy can be used to address hypogonadism and promote secondary sexual characteristics. Regular cardiac monitoring is essential due to the progressive nature of the cardiomyopathy. Genetic counseling is recommended for affected families.

Common questions about Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome